IP Library Granted Patent US 7,482,467
Granted Patent B2
US 7,482,467 · App. 11/948,073 · Granted Jan 27, 2009

N-thiolated 2-oxazolidinone-derived antibiotics

Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,482,467
App. No.
11/948,073
Granted
Jan 27, 2009
Kind
B2
Abstract

This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties against Staphylococcus spp., including methicillin resistant Staphylococcus aureus (MRSA), and Bacillus spp., including Bacillus anthracis.

Claims (15)

1. A method of treating bacterial infection comprising administering an effective amount of a N-thiolated-2-oxazolidinone selected from the group consisting of

to a patient in need thereof.

2. The method of claim 1 , wherein the bacterium is a Staphylococcus.

3. The method of claim 1 , wherein the Staphylococcus is a methicillin-resistant Staphylococcus.

4. The method of claim 3 , wherein said methicillin-resistant Staphylococcus is selected from the group consisting of MRSA USF919, MRSA USF920, MRSA USF652, MRSA USF653, MRSA USF654, MRSA USF655, MRSA USF656, MRSA USF657, MRSA USF658 and MRSA USF659.

5. The method of claim 1 wherein the bacterium is a Bacillus.

6. The method of claim 5 wherein the Bacillus spp. is selected from the group consisting of B. anthracis, B. globigii, B. thurigensis, B. megaterium, B. subtilis, B. cereus and B. coagulans.

7. The method of claim 1 wherein the N-thiolated 2-oxazolidinone compound is administered in a pharmaceutically acceptable carrier.

8. A method of inhibiting growth of a bacterium comprising the step of administering an effective amount of an N-thiolated 2-oxazolidinone compound selected from the group consisting of,

or a salt or hydrate thereof, to the bacterium.

9. The method of claim 8 wherein the bacterium is a Staphylococcus.

10. The method of claim 1 , wherein the Staphylococcus is a methicillin-resistant Staphylococcus.

11. The method of claim 3 , wherein said methicillin-resistant Staphylococcus is selected from the group consisting of MRSA USF919, MRSA USF920, MRSA USF652, MRSA USF653, MRSA USF654, MRSA USF655, MRSA USF656, MRSA USF657, MRSA USF658 and MRSA USF659.

12. The method of claim 1 wherein the bacterium is a Bacillus.

13. The method of claim 5 wherein the Bacillus is selected from the group consisting of B. anthracis, B. globigii, B. thurigensis, B. megaterium, B. subtilis, B. cereus and B. coagulans.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 20, 2010
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025016/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2008
From: TUROS, EDWARD; MISHRA, RAJESH KUMAR
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 020646/0247 →
Continuity (3)
Division 1138215700 · May 8, 2006
Provisional Application 6067829200 · May 6, 2005
Related Publication 20080119533A1 · May 22, 2008